G. Frederick Wilkinson is departing Actavis plc to join Impax Laboratories Inc. as president and chief executive officer.

Impax Laboratories, G. Frederick Wilkinson, chief executive officer, CEO, president, Larry Hsu, Actavis, Robert Burr, specialty pharmaceutical company

Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Impax hires Actavis exec as CEO

April 21st, 2014

HAYWARD, Calif. – G. Frederick Wilkinson is departing Actavis plc to join Impax Laboratories Inc. as president and chief executive officer.

The specialty pharmaceutical company said Monday that Wilkinson is due to take the CEO reins on April 29. He will succeed Larry Hsu, who is retiring.

The appointment of Wilkinson wraps up a transition process that began last year when Hsu announced his decision to retire, according to Impax. Hsu will continue to serve on the Impax board.

Wilkinson currently is president of Actavis Global Research and Development. Actavis said Monday that he is slated to leave the company effective April 25.

"I am grateful to Dr. Hsu and the board for the privilege to lead the future direction of the company and reinforce a quality-first culture," Wilkinson said in a statement on his new role as Impax president and CEO. "This is a great company, with a strong balance sheet, experienced business team and multiple product opportunities. I look forward to building on Impax's success."

Wilkinson, 57, joined Watson Pharmaceuticals Inc. (now Actavis) as executive vice president of global brands in September 2009. Before that, he was president and chief operating officer of Duramed Pharmaceuticals Inc., the proprietary products arm of Barr Pharmaceuticals Inc., from 2006 to 2009. And prior to joining Duramed, he was president and CEO of Columbia Laboratories Inc. from 2001 to 2006. From 1996 to 2001, Wilkinson was senior vice president and COO of Watson. Before joining Watson, he spent 16 years at Sandoz in various senior management positions.

"A long-time industry leader, Fred's extensive experience in managing generic, brand, R&D, and regulatory and compliance activities, together with his track record in driving change, delivering growth, advancing pipeline products and driving innovation, make him the perfect candidate for this role," stated Robert Burr, chairman of Impax. "I have every confidence that Fred's vision and passion will translate into remarkable success for Impax. The board would like to thank Dr. Hsu for his incredible dedication and commitment over the last 18 years and for positioning the company for its next phase of growth."